Related Experiment Videos
Tyrosinase inhibition: its role in suntanning and in albinism
Abstract:
Tyrosinase inhibitor (molecular weight less than 5000; extracted from various melanomas) fully inhibits soluble tyrosinase but only partially inhibits tyrosinase "aggregated" into melanosomes; the inhibitor can be inactivated by ultraviolet light. S91 Albinotyrosinase Type B apparently cannot "aggregate" into melanosomes because its protein carrier is genetically altered. Therefore, albinotyrosinase remains vulnerable to its inhibitor and cannot produce melanin, even though the enzyme has a functioning active center.
Insights
A novel tyrosinase inhibitor effectively blocks soluble tyrosinase but shows limited efficacy against melanosome-aggregated forms. Genetic alterations in albinotyrosinase prevent aggregation, rendering it susceptible to inhibition and blocking melanin production.
Area of Science:
- Biochemistry
- Melanogenesis research
- Enzyme inhibition studies
Background:
- Tyrosinase is a key enzyme in melanin production.
- Melanosomes are cellular organelles where melanin is synthesized and stored.
- Melanoma research involves understanding tyrosinase activity and inhibition.
Purpose of the Study:
- To investigate the efficacy of a low molecular weight tyrosinase inhibitor.
- To determine the inhibitor's effect on soluble versus aggregated tyrosinase.
- To explore the role of melanosome aggregation in tyrosinase inhibition.
Main Methods:
- Extraction of a tyrosinase inhibitor (MW < 5000) from melanomas.
- Assaying inhibitor activity against soluble tyrosinase.
- Assaying inhibitor activity against tyrosinase aggregated into melanosomes.
- Investigating the effect of ultraviolet light on inhibitor activity.
- Examining S91 Albinotyrosinase Type B for its aggregation properties.
Main Results:
- The inhibitor fully inhibited soluble tyrosinase.
- Partial inhibition was observed for tyrosinase aggregated into melanosomes.
- Ultraviolet light inactivated the tyrosinase inhibitor.
- S91 Albinotyrosinase Type B, due to a genetically altered protein carrier, could not aggregate into melanosomes.
- Albinotyrosinase remained vulnerable to the inhibitor, preventing melanin synthesis despite a functional active center.
Conclusions:
- Melanosome aggregation influences tyrosinase inhibitor efficacy.
- Genetic factors affecting protein carriers can impact enzyme susceptibility to inhibitors.
- Targeting tyrosinase aggregation may offer strategies for controlling melanin production.